Evotec (EVO) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Evotec is expected to announce its quarterly earnings before the market opens on August 13th, with analysts predicting a loss of ($0.12) per share and revenue of $202.02 million.
• The company's stock recently rose by 1.3% to $3.80, although its trading volume was significantly below the average.
• A hedge fund, Bank of America Corp DE, significantly increased its stake in Evotec by 262.5% in the fourth quarter, now owning approximately 12,828 shares.

Evotec (NASDAQ:EVO - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect Evotec to post earnings of ($0.12) per share and revenue of $202.02 million for the quarter.

Evotec Price Performance

EVO stock traded down $0.14 during trading on Monday, hitting $3.79. 49,376 shares of the company traded hands, compared to its average volume of 98,640. The stock's 50-day simple moving average is $4.08 and its 200 day simple moving average is $3.99. The company has a quick ratio of 1.93, a current ratio of 2.03 and a debt-to-equity ratio of 0.46. Evotec has a 1 year low of $2.84 and a 1 year high of $5.64.

Analyst Ratings Changes

A number of research firms recently issued reports on EVO. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Evotec in a report on Thursday, May 15th.

Institutional Investors Weigh In On Evotec

A hedge fund recently raised its stake in Evotec stock. Bank of America Corp DE raised its holdings in shares of Evotec AG (NASDAQ:EVO - Free Report) by 262.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 12,828 shares of the company's stock after acquiring an additional 9,289 shares during the period. Bank of America Corp DE's holdings in Evotec were worth $53,000 at the end of the most recent reporting period. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.